Abstract
Glycated haemoglobin (HbA1c) is currently the gold standard for glucose monitoring in patients with diabetes, and has been increasingly adopted as a criteria for diabetes diagnosis. However, conditions that determine alterations in haemoglobin metabolism can interfere with the reliability of HbA1c measurements.
Glycated albumin and fructosamine (total glycated serum proteins) are alternative markers of glycaemia, which have been recognised to provide additional information to HbA1c or to provide a reliable measure when HbA1c is observed not to be dependable. Additionally, while HbA1c monitors the exposure to circulating glycaemia in the previous 3 months, glycated albumin and fructosamine represent exposure for a shorter period, which may be beneficial to monitor rapid metabolic alterations or changes in diabetes treatment.
The present review further discusses the relative value of HbA1c, glycated albumin, and fructosamine, in prediabetes and diabetes diagnosis, evaluation of glucose variability, and complications risk prediction. Also, a novel molecular role for albumin is presented by which glycated albumin contributes to glucose intolerance development and thus to progression to diabetes, besides the role of glycated albumin as a pro-atherogenic factor.
Keywords: HbA1c, fructosamine, glycated albumin, diabetes, diagnosis, glucose variability, glucose monitoring.
Current Diabetes Reviews
Title:HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Volume: 12 Issue: 1
Author(s): Rogerio Tavares Ribeiro, Maria Paula Macedo and Joao Filipe Raposo
Affiliation:
Keywords: HbA1c, fructosamine, glycated albumin, diabetes, diagnosis, glucose variability, glucose monitoring.
Abstract: Glycated haemoglobin (HbA1c) is currently the gold standard for glucose monitoring in patients with diabetes, and has been increasingly adopted as a criteria for diabetes diagnosis. However, conditions that determine alterations in haemoglobin metabolism can interfere with the reliability of HbA1c measurements.
Glycated albumin and fructosamine (total glycated serum proteins) are alternative markers of glycaemia, which have been recognised to provide additional information to HbA1c or to provide a reliable measure when HbA1c is observed not to be dependable. Additionally, while HbA1c monitors the exposure to circulating glycaemia in the previous 3 months, glycated albumin and fructosamine represent exposure for a shorter period, which may be beneficial to monitor rapid metabolic alterations or changes in diabetes treatment.
The present review further discusses the relative value of HbA1c, glycated albumin, and fructosamine, in prediabetes and diabetes diagnosis, evaluation of glucose variability, and complications risk prediction. Also, a novel molecular role for albumin is presented by which glycated albumin contributes to glucose intolerance development and thus to progression to diabetes, besides the role of glycated albumin as a pro-atherogenic factor.
Export Options
About this article
Cite this article as:
Ribeiro Tavares Rogerio, Macedo Paula Maria and Raposo Filipe Joao, HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions, Current Diabetes Reviews 2016; 12(1) . https://dx.doi.org/10.2174/1573399811666150701143112
DOI https://dx.doi.org/10.2174/1573399811666150701143112 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Intracranial Stents Past, Present and the Future Trend: Stents Made with Nano-particle or Nanocomposite Biomaterials
Current Medicinal Chemistry Hypothyroidism and Atherosclerosis-Possible Implication of the Renin-Angiotensin System
Current Hypertension Reviews Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
Current Pharmaceutical Design Cardiac Regeneration: Stem Cells and Beyond
Current Medicinal Chemistry 3D-QSAR analysis of MCD inhibitors by CoMFA and CoMSIA
Combinatorial Chemistry & High Throughput Screening Periodontal Disease and Periodontal Tissue Regeneration
Current Stem Cell Research & Therapy Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure
Current Cardiology Reviews The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design High Prevalence of AH in HIV Patients on ART, in Bahia, Brazil
Current HIV Research Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Hypocholesterolemia
Current Vascular Pharmacology Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets